The Radiochemistry and Instrumentation Support Laboratory (RISL) is one of the core facilities and shared resources of The Ohio State University (OSU) Comprehensive Cancer Center (CCC). The purposes of the RISL are fivefold: (1) to provide custom synthesis of radiochemicals not available commercially to investigators of the OSUCCC, (2) to perform purification of custom preparations of chemically-labile radiochemicals, (3) to aid in the purchase of radiochemicals, advice on the use of radiochemical products and equipment, and provide radiation safety expertise to the CCC, (4) to provide organic chemical support services [synthesis, isolation, structure determination, chemistry expertise] for CCC investigators, and (5) to maintain chemical instrumentation for the isolation and structure determination of carcinogens, drugs, metabolites, and biochemical compounds and general equipment for biochemical/biological research. Robert W. Brueggemeier, Ph.D. is director of the Radiochemistry and Instrumentation Support Laboratory and is involved with projects both as a shared resource person and as a principal investigator within he OSUCCC. Michael V. Darby, Ph.D. serves as the full-time synthetic radiochemist in the Radiochemistry Laboratory. Drs. Brueggemeier and Darby co-direct a graduate research assistant and work closely with cost doctoral research and technicians on the various projects utilizing radiochemistry and chemistry services. Several research and service activities were expanded or introduced since July 1995. These additional services include development of methods of determination of 8-hydroxydeoxyguanosine levels by HPLC- electrochemical detection, expansion of iodination procedures using a variety of reagents, acquisition and installation of new instrumentation and relocation of instruments into laboratory facilities where the instruments are more effectively utilized. The RISL will continue to be an effective radiochemistry and instrumentation support facility for cancer research, diagnosis, or treatment that is encompassed in the OSU Comprehensive Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-27
Application #
6563730
Study Section
Project Start
2001-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
27
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Rahnemai-Azar, Amir A; Cloyd, Jordan M; Weber, Sharon M et al. (2018) Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. J Clin Transl Hepatol 6:97-104
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Kodigepalli, Karthik M; Bonifati, Serena; Tirumuru, Nagaraja et al. (2018) SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle 17:1124-1137
Zhang, Tianyu; Xu, Jielin; Deng, Siyuan et al. (2018) Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data. PLoS One 13:e0196351
Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753
LaPak, Kyle M; Vroom, Dennis C; Garg, Ayush A et al. (2018) Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget 9:25386-25401
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Kaffenberger, Benjamin H; Hinton, Alice; Krishna, Somashekar G (2018) The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 79:659-663.e2
Chen, Shuliang; Bonifati, Serena; Qin, Zhihua et al. (2018) SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-?B and interferon pathways. Proc Natl Acad Sci U S A 115:E3798-E3807

Showing the most recent 10 out of 2602 publications